Adaptimmune Therapeutics plc
ADAPNASDAQHealthcare
$0.05
$-0.00(-3.00%)
Market Cap$75157679
P/E Ratio—
52W High$0.86
52W Low$0.0202
Adaptimmune Therapeutics plc (ADAP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ADAP · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 12, 2025EPS Actual
-$0.07
Est. -$0.09 · +22.2%
Revenue
—
Est. $0.01B
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 12, 2025
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
ADAP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.09 | -$0.07 | +22.2% | — | $0.01B | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.15 | -$0.11 | +26.7% | $0.01B | $0.01B | +5.8% |
| — Q2 FY2025 | May 13, 2025 | -$0.18 | -$0.18 | +0.0% | $0.01B | $0.01B | -15.9% |
| ▼ Q1 FY2025 | Mar 24, 2025 | -$0.17 | -$0.26 | -52.9% | $0.00B | $0.01B | -61.7% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.17 | -$0.07 | +58.8% | $0.04B | $0.01B | +266.2% |
| ▲ Q3 FY2024 | Aug 12, 2024 | -$0.07 | $0.24 | +442.9% | $0.01B | $0.01B | +14.8% |
| ▼ Q2 FY2024 | May 15, 2024 | -$0.16 | -$0.18 | -12.5% | $0.01B | $0.01B | -47.1% |
| ▼ Q1 FY2024 | Mar 6, 2024 | -$0.12 | -$0.24 | -100.0% | $0.00B | $0.01B | -17.2% |
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.09
EPS Surpr.
+22.2%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.15
EPS Surpr.
+26.7%
Revenue
$0.01B
Q2 FY2025
May 13, 2025
EPS Actual
-$0.18
EPS Est.
-$0.18
EPS Surpr.
+0.0%
Revenue
$0.01B
Q1 FY2025
Mar 24, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.17
EPS Surpr.
-52.9%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.07
EPS Est.
-$0.17
EPS Surpr.
+58.8%
Revenue
$0.04B
Q3 FY2024
Aug 12, 2024Beat
EPS Actual
$0.24
EPS Est.
-$0.07
EPS Surpr.
+442.9%
Revenue
$0.01B
Q2 FY2024
May 15, 2024Miss
EPS Actual
-$0.18
EPS Est.
-$0.16
EPS Surpr.
-12.5%
Revenue
$0.01B
Q1 FY2024
Mar 6, 2024Miss
EPS Actual
-$0.24
EPS Est.
-$0.12
EPS Surpr.
-100.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q3 FY2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q2 FY2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q1 FY2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q4 FY2025 | $-0.05 | $-0.03 | $-0.01 | 1 |
| Q3 FY2025 | $-0.07 | $-0.05 | $-0.03 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 12, 2025 | +22.2% | $0.03 | $0.04 | +25.00% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +26.7% | $0.08 | $0.08 | +1.82% |
| ▲ Q2 FY2025 | May 13, 2025 | +0.0% | $0.30 | $0.25 | -15.31% |
| ▼ Q1 FY2025 | Mar 24, 2025 | -52.9% | $0.29 | $0.28 | -4.81% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +58.8% | $0.79 | $0.77 | -2.91% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +442.9% | $0.99 | $1.09 | +9.82% |
| ▼ Q2 FY2024 | May 15, 2024 | -12.5% | $1.15 | $1.24 | +7.83% |
| ▼ Q1 FY2024 | Mar 6, 2024 | -100.0% | $1.46 | $1.71 | +17.12% |
Q4 FY2025+25.00%
Report Date
Nov 12, 2025
EPS Beat/Miss
+22.2%
Price Before
$0.03
Price After
$0.04
Q3 FY2025+1.82%
Report Date
Aug 13, 2025
EPS Beat/Miss
+26.7%
Price Before
$0.08
Price After
$0.08
Q2 FY2025-15.31%
Report Date
May 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.30
Price After
$0.25
Q1 FY2025-4.81%
Report Date
Mar 24, 2025
EPS Beat/Miss
-52.9%
Price Before
$0.29
Price After
$0.28
Q4 FY2024-2.91%
Report Date
Nov 13, 2024
EPS Beat/Miss
+58.8%
Price Before
$0.79
Price After
$0.77
Q3 FY2024+9.82%
Report Date
Aug 12, 2024
EPS Beat/Miss
+442.9%
Price Before
$0.99
Price After
$1.09
Q2 FY2024+7.83%
Report Date
May 15, 2024
EPS Beat/Miss
-12.5%
Price Before
$1.15
Price After
$1.24
Q1 FY2024+17.12%
Report Date
Mar 6, 2024
EPS Beat/Miss
-100.0%
Price Before
$1.46
Price After
$1.71
Avg Beat Reaction+3.68%
Avg Miss Reaction+6.71%
Beat Rate5 / 8 quarters
Largest Move+25.00% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ADAP ends December
Adaptimmune Therapeutics plc (ADAP) most recently reported earnings on November 12, 2025 for Q4 FY2025, posting EPS of $-0.07 — beating the analyst consensus of $-0.09 by +22.2%. ADAP has beaten EPS estimates for 3 consecutive quarters. The next ADAP earnings date is expected around September 1, 2026.
Each quarter, investors track ADAP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ADAP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ADAP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ADAP earnings · 5 questionsAdaptimmune Therapeutics plc's next earnings report is expected around September 1, 2026. ADAP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ADAP historically reports after market close (AMC).
ADAP earnings datewhen is ADAP earningsADAP next earnings datewhen does ADAP report earningsADAP earnings calendar
▸ Source: FMP · Adaptimmune Therapeutics plc SEC filings · US GAAP · Adaptimmune Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026